Literature DB >> 29148260

Peri-implant parameters and C-reactive protein levels among patients with different obesity levels.

Fahim Vohra1, Fahad Alkhudhairy2, Abdulaziz A Al-Kheraif3, Zohaib Akram4, Fawad Javed5.   

Abstract

BACKGROUND: It is hypothesized that peri-implant conditions are worse with increasing severity of obesity, because systemic low-grade inflammatory marker (C-reactive protein [CRP]) is higher in severe form of obese individuals.
PURPOSE: The aim of the cross-sectional retrospective study was to compare clinical and radiographic peri-implant inflammatory parameters in patients with different levels of obesity and correlate these parameters with CRP levels.
MATERIALS AND METHODS: Eighty-four patients who participated in this study were divided into 4 groups: class I obese (group 1), class II obese (group 2), class III obese (group 3), and nonobese individuals (group 4) were included. Clinical (plaque index [PI], bleeding on probing [BOP], probing depth [PD]) and radiographic (marginal bone loss [MBL]) peri-implant parameters were recorded. Serum CRP were quantified using enzyme-linked immunosorbent assay (ELISA). Clinical peri-implant parameters and serum CRP concentrations were analyzed using 1-way analysis of variance. The Pearson correlation coefficient was used to analyze correlations of CRP levels with any of the clinical and radiographic parameters assessed.
RESULTS: Peri-implant PI, BOP, PD, and MBL were significantly higher in group-1, -2, and -3 patients as compared to nonobese individuals (P < .05). Peri-implant PI, BOP, PD, and MBL were significantly higher in obese patients of group-2 and group-3 as compared to obese patients in group-1 (P < .01). Mean PI, BOP, PD, and MBL were comparable between group-2 and group-3 patients (P > .05). A significant positive correlations were found between CRP levels and BOP (P = .0148) and PD (P = .0425); and significant negative correlation was found for MBL in group 3, respectively (P = .0212).
CONCLUSION: Clinical and radiographic peri-implant inflammatory parameters and serum CRP were significantly high in patients with severe form of obesity. Serum CRP levels correlated with peri-implant bleeding in obese patients. These findings are preliminary and long-term controlled trials are recommended to support these outcomes.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  C-reactive protein; alveolar bone loss; bleeding on probing; dental implants; obesity

Mesh:

Substances:

Year:  2017        PMID: 29148260     DOI: 10.1111/cid.12556

Source DB:  PubMed          Journal:  Clin Implant Dent Relat Res        ISSN: 1523-0899            Impact factor:   3.932


  5 in total

1.  Assessment of Levels of C-Reactive Proteins and Interleukin 6 in Patients with Peri-Implantitis: A Case-Control Study.

Authors:  Aditya Khichy; Ruhani Khichy; Ravpreet Singh; Yashika Bali; Supreet Kaur; Tarunpreet Kaur Gill
Journal:  J Pharm Bioallied Sci       Date:  2021-06-05

2.  Evaluation of tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-1β levels among subjects vaping e-cigarettes and nonsmokers.

Authors:  Dharmendra Kumar Sinha; Ashish Kumar; Mohsin Khan; Ritu Kumari; Mritunjay Kesari
Journal:  J Family Med Prim Care       Date:  2020-02-28

3.  The Relationship between Circulating ANGPTL8/Betatrophin Concentrations and Adult Obesity: A Meta-Analysis.

Authors:  Jingjing Ye; Yu Qin; Dong Wang; Ling Yang; Guoyue Yuan
Journal:  Dis Markers       Date:  2019-10-22       Impact factor: 3.434

Review 4.  Should Quality of Glycemic Control Guide Dental Implant Therapy in Patients with Diabetes? Focus on: Peri-Implant Diseases.

Authors:  Salwa Aldahlawi; Dalia Nourah; Sebastiano Andreana
Journal:  Clin Cosmet Investig Dent       Date:  2021-04-21

5.  Association between Neutrophil-to-Lymphocyte Ratio with Abdominal Obesity and Healthy Eating Index in a Representative Older Spanish Population.

Authors:  Elena Rodríguez-Rodríguez; Ana M López-Sobaler; Rosa M Ortega; M Luisa Delgado-Losada; Ana M López-Parra; Aránzazu Aparicio
Journal:  Nutrients       Date:  2020-03-23       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.